We have also included levels for the related ERα, for which functionally consequences at the protein level can be deduced: Tumours that stain for ERα in routine clinical pathology assessment (using well-validated IHC protocols, denoted ‘ERα+’ in Fig. 5b) respond to endocrine treatment, whereas ERα-negative tumours do not. This evidence concerns the gene ESR1 and neoplasm.